Grants for For profit organizations other than small businesses - Health

This grant provides funding for researchers to study how various stressors experienced during adulthood affect the biological mechanisms of aging and related health outcomes in experimental model systems.

The City of Pittsburg Façade Improvement Grant Program aims to stimulate investment in the local business community by offering up to $10,000 for façade enhancements to eligible businesses. This initiative aligns with the city's mission to support and foster the growth of its local businesses, recognizing them as essential for community vitality, opportunity creation, and creativity. By focusing on visible improvements to storefronts, the program directly contributes to the beautification of public-facing areas and the overall image of the city. The primary beneficiaries of this program are small, brick-and-mortar businesses with public-facing storefronts located within Pittsburg city limits and holding an active City of Pittsburg Business License. Shopping centers with five or fewer tenants are also eligible. The program explicitly excludes home-based businesses and businesses that sell tobacco, alcohol, cannabis products, or adult materials. The impact goal is to create more inviting storefronts, improve neighborhood characteristics, encourage reinvestment in older buildings, and increase potential foot traffic for businesses, ultimately benefiting the businesses, their customers, and the wider Pittsburg community. The program prioritizes enhancements and beautification of public-facing building façades that will improve the image and characteristics of the building, the business, and the City. Specific focuses include signage, awnings, exterior paint (including anti-graffiti), architectural treatments, stucco, cladding, and/or siding repair, windows, front entrance doors, exterior lighting, planter boxes, and bicycle racks. The City seeks businesses that will provide the maximum return on investment and long-lasting benefits. A property-owner-led application is highly encouraged to ensure uniform projects, though individual tenants can also apply. The expected outcomes include a more aesthetically pleasing urban environment, increased business visibility, and a more inviting experience for customers. Measurable results will include the number of façades improved, the amount of grant funds dispersed (up to $10,000 per applicant from a $30,000 budget), and potentially qualitative feedback on improved neighborhood characteristics and increased foot traffic. The City's strategic priority is to invest in its local businesses to help them thrive, with a theory of change that by improving the physical appearance of business fronts, the city can stimulate economic activity, enhance community pride, and foster a more vibrant local economy.

The National Institute of Neurological Disorders and Stroke (NINDS), in collaboration with the National Institute of Mental Health (NIMH), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications that propose the development and early stage validation of novel humanized small animal models and/or human cellular microphysiological systems for NeuroHIV preclinical research. The goal of this initiative is to promote a significant improvement in the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the central nervous system (CNS) in the modern antiretroviral therapy (ART) era under conditions of viral suppression. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024. This NOFO will utilize the R61/R33 activity code. Details of the planned NOFO are provided below.

This funding opportunity provides financial support to obstetrics, gynecology, and family medicine practices in New York State to implement an integrated mental health care model, improving services for perinatal patients, especially in underserved areas.

This grant provides funding to Minnesota-based organizations to develop and expand primary care residency programs, particularly in underserved and rural areas, to help address the shortage of primary care physicians in the state.

This program provides competitive funding for community organizations and local governments to build or improve public facilities that support work, education, and health monitoring in response to the COVID-19 pandemic.

The United States Agency for International Development (USAID) is seeking applications for a Cooperative Agreement with a Total Estimated Amount of $45,000,000 from qualified entities to implement the program entitled Strengthening Integrated Health Services Activity (SIHSA) in Sierra Leone.USAID anticipates awarding a five-year cooperative agreement (CA) to advance and sustain improved health outcomes for Sierra Leoneans with a focus on, but not limited to: children under five, pregnant and postpartum women, youth and especially adolescent girls, and women and children living in hard-to-reach areas with limited access to health services. Special attention will be paid to those especially vulnerable within these groups, such as the disabled, gender andsexual minorities (GSM), and ethnic and religious minorities.SIHSA seeks to build a sustainable and resilient health system response to improving access, quality, and effectiveness of family planning (FP), reproductive health (RH), maternal, newborn and child health (MNCH), adolescent health, and malaria services. In addition, SIHSA aims at strengthening communities;apos; active engagement for community-driven solutions to improve health outcomes. Finally, SIHSA seeks to promote a paradigm shift within the health system, supporting system-wide action, especially at community and district levels, including reforms that act on the foundations of the health system and create opportunities for partnering with the local civil society and private sector for improved health outcomes.

This funding opportunity supports projects that improve the competitiveness of California's specialty crops, benefiting a wide range of organizations, including nonprofits, government entities, and educational institutions.

This funding opportunity supports organizations in developing educational resources and outreach initiatives to reduce tobacco use and improve asthma health among healthcare professionals in the District of Columbia.

This funding opportunity provides financial support to community organizations that deliver non-clinical suicide prevention services for veterans and their families, aiming to improve mental health access and overall well-being.

This grant provides funding for organizations in Massachusetts and New York that support young individuals facing intellectual disabilities, learning disabilities, mental health challenges, or substance use disorders, with a focus on historically marginalized communities.

The Arizona Department of Health Services (ADHS) Bureau of Women’s and Children’s Health (BWCH) oversees Adolescent Health programming to improve the health and well-being of young people in the state. As of 2005, BWCH has been administering state lottery funds for the prevention of teen pregnancies and sexually transmitted infections (STIs). According to the Arizona Vital Statistics, from 2011 to 2021, the teen birth rate for Arizona teenagers ages fifteen through nineteen (15-19) has declined from thirty-six point nine (36.9) to fifteen point three (15.3) per 1,000 females. The repeat birth rates of youth of the same age, who had already had a child decreased from 142.7 in 2011 to 135.8 per 1,000 in 2021. Despite the declines, birth rates for Arizona teens ages fifteen through nineteen (15-19)   exceeds   the   national   rate   of   thirteen   point   nine   (13.9)   in   2021 (https://blogs.cdc.gov/nchs/2023/01/20/7245/). Arizona's racial and ethnic groups exhibit significant disparities in teen pregnancy rates, with Hispanic, American Indian, and African American females aged nineteen (19) or younger experiencing the highest rates. In 2021, American Indian youth had a notably elevated pregnancy rate of sixteen point three (16.3) per 1,000 females, surpassing the state average of ten point six (10.6) per 1,000. Similarly, rates for Hispanic or Latino youth were fourteen point four (14.4) per 1,000, and for Black or African American youth, they were twelve point six (12.6) per 1,000, both above the state average, while rates for White Non-Hispanics six (6) per 1,000 and Asian or Pacific Islanders three point four (3.4) per 1,000 were considerably lower. Teen pregnancy is intricately linked with complex factors such as school failure, behavioral issues, and family challenges, which often hinder youths’ ability to avoid pregnancy. Positive Youth Development (PYD) programs present a promising approach by emphasizing the enhancement of protective factors over merely addressing risk behaviors. These programs have shown efficacy in reducing sexual risk behaviors, Human immunodeficiency virus (HIV), other sexually transmitted diseases (STDs), and unintended pregnancies. By fostering ongoing development and maturation, PYD programs empower youth to recognize and manage risk-taking behaviors, making them a viable strategy for teen pregnancy prevention (Gavin et al., 2010). According to the 2021 Arizona Surveillance STD case data, forty-nine percent (49%) of STD cases (chlamydia, gonorrhea, and syphilis) in Arizona were among adolescents under the age of twenty-five (25). Since 2019, the rate of chlamydia among teenagers fifteen through nineteen (15-19) years old has been slowly decreasing but still remains high at 2,031 per 100,000 in 2019 to 1,729 per 100,000 in 2021. For gonorrhea, the rate among these teenagers increased from 384 per 100,000 in 2019 to 467 per 100,000 in 2021. As for syphilis, in 2019, twenty-two (22) per 100,000 fifteen through nineteen (15-19) year-old teenagers were reported to have syphilis, increasing to twenty-six (26) per 100,000 in 2021. Regarding STDs/STIs, major disparities between Arizona’s racial and ethnic groups also persist. The Arizona 2021 Annual STD Report indicates that Black (994 per 100,000) and American Indian/Alaska Native (787 per 100,000) populations have consistently higher rates of chlamydia, the Black population (763 per 100,000) continues to have the highest rate of gonorrhea, and the American Indian/Alaska Native (172 per 100,000) and Black (123 per 100,000) populations have the highest rates of syphilis, surpassing their Hispanic, White, and Asian/Pacific Islander counterparts. Financial Notes: Approximately $700,000.00 will be available each Grant year for a five (5) year grant period to provide services to youth for the prevention of teen pregnancies and STIs. Annual funding for services will be provided during the state fiscal year, from July through June; Therefore, the first and last years of funding will be partial funding: first year funded upon award through June 30, 2025; fifth year from July 1, 2029 through September 30, 2029. Budgets will be reviewed annually and may be decreased based on: 1. Changes in state lottery funding allocations. 2. Failure to meet the number of youths proposed to be served; or meet the required program completion by youth for Teen Pregnancy Prevention Programming. 3. Failure to comply with Grant requirements. 4. Negative audit findings. 5. Failure to spend budget funds efficiently.

This funding opportunity provides financial support to nonprofit organizations in New York and Massachusetts that enhance their capacity to serve young people with intellectual and learning disabilities, mental health challenges, and substance use disorders, particularly those from historically marginalized communities.

The National Institute of Mental Health (NIMH) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications encouraging foundational research projects that seek to refine and test valid methods for characterizing preteen suicide risk and protective factors across multiple domains, and for operationalizing suicide thoughts and behavior (STBs) and nonsuicidal self-injury (NSSI) among preteen youth (ages 8-12). An emphasis is placed on the inclusion of sub-populations of youth that experience health disparities and may have been underrepresented in prior youth suicide research. Studies may focus on developing new or adapting developmentally and culturally appropriate methods for assessing and characterizing risk and protective factors, examining the acceptability and utility of existing assessment methods, evaluating the relevance of risk and protective factors for diverse preteen youth and their families, modeling risk-factor trajectories, and refining sampling strategies. The research projects funded through this announcement will participate in a research consortium with other R01 recipients. In addition, each research site will work with the Data Coordinating Center (DCC) site (supported by a companion announcement) to share and analyze data, recommend candidate measures that will be included as common data elements in future research and practice contexts,and identify optimal approaches for sampling individuals from underrepresented backgrounds. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects, and to consult with NIH in order to submit responsive applications. The NOFO is expected to be published in Summer 2023, with an expected application due date in Fall 2023. This NOFO will utilize the R01 activity code. Details of the planned NOFO are provided below.

Despite huge advances in the development of novel medical therapies, Americans still live with poor health outcomes and suffer from the ill-effects of disease. Current medical research and the medical delivery system in the United States focus primarily on the reactive treatment of illnesses, despite the fact that many diseases or their ill-effects are preventable.The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Specific PHO interest areas include:Novel prevention, detection and prophylactic treatment methods for disease: Novel and scalable methods for early detection of disease and illness including the use of low/no-cost sensing modalities. Prophylactic approaches to prevention of diseases and harmful disease outcomes. Methods for continuous and widespread sensing of health state and early disease indicators that can be deployed at population-scale.Population-level approaches to increase the adoption of prevention and wellness behaviors: Early indicators of disease and pre-disease states and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness building methods for individuals. Methods to inform and educate individuals about healthy behaviors including lifestyle and preventative medical measures. Methods that incentivize individuals to adopt and maintain healthy behaviors. Novel approaches to increasing individual healthspan and independence even in the absence of disease.System innovation for the delivery of proactive health outcomes: Novel, robust and predictive surrogates for long-term health outcomes with associated epidemiological models. Valuation models for long-term treatment effects for vaccination, screening and other public health interventions. New funding and delivery models for preventative intervention.Other high-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy advocacy, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The Women’s Business Development Council (WBDC) is offering the Torrington Grant Program, a grant designed to foster the growth of businesses located in Torrington, Connecticut. This initiative aligns with the WBDC's mission to support and empower businesses, particularly by providing crucial financial assistance that can contribute to economic development within the targeted city. The program specifically excludes the use of funds for operating expenses, real estate improvements, reimbursement for past purchases, or debt repayment, emphasizing a focus on growth-oriented investments rather than day-to-day operational costs. The primary beneficiaries of this grant are for-profit businesses situated in Torrington, Connecticut, that meet specific criteria. These businesses must have been in operation for at least two years with a record of sales, demonstrate annual sales/revenue between $25,000 and $2,000,000 in the last twelve months, be registered in Connecticut, and hold a zoning permit from the City of Torrington. Additionally, they must be in good standing with the CT Department of Revenue Services, possess an established business checking account, and utilize a formal digital bookkeeping/financial system. The owner must also be at least 18 years old. The impact goal is to stimulate economic vitality and stability within Torrington by supporting established local businesses. The program prioritizes businesses that are poised for growth and are operating within a structured financial framework. There is a clear focus on financial transparency and stability, as evidenced by the requirement for digital bookkeeping systems and good standing with the Department of Revenue Services. Certain types of businesses are explicitly ineligible, including childcare businesses (though WBDC offers other programs for them), businesses that have previously received a WBDC grant, current WBDC vendors or contractors, and a range of businesses such as medical marijuana, liquor stores, adult businesses, vape/tobacco shops, gambling-related businesses, gun stores, cash advance/pawn shops, and collection agencies. This selectivity ensures that the grants are directed towards businesses that align with the WBDC's strategic vision for community development and ethical business practices. Grants will range from $2,500 to $10,000. The expected outcomes include a measurable increase in the capacity and reach of the recipient businesses, contributing to job creation and sustained economic activity within Torrington. By providing financial resources to qualifying businesses, the WBDC aims to strengthen the local business ecosystem and encourage long-term prosperity. This grant program is a direct manifestation of the WBDC's strategic priority to support local economies through targeted financial aid, operating under the theory of change that direct investment in compliant, established businesses will lead to enhanced economic stability and growth.

This funding opportunity supports educational institutions, nonprofits, and government agencies in Hawaiʻi to develop projects that boost local business growth, job creation, and sustainability on the island.

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. HSF expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. HSF supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change.Considering the current healthcare challenges that we face today, the goal of achieving better health outcomes is a moving target that requires daring and adaptable solutions. HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support:Breakthrough Technologies: Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions. Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods. Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need. Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems. Novel approaches to diagnose and treat diseases of the lymphatic system, particularly rare diseases, with a focus on the effects of genetic expression in the lymphatic system and/or models demonstrating the relationship between lymphatic dysfunction and health and disease.Transformative Tools: Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care. Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease. Development of bionics to restore sight, hearing, taste, or smell. Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders. Synthetic biology approaches to diagnosing, treating, and/or curing a multitude of diseases. Novel physics and/or chemistry-based approaches to improve imaging that reduces cost, increases availability, expands capability, improves resolution, reduces exposure to radiation, and accommodates pediatric patient populations. Integrated sensing and delivery devices for treating and diagnosing chronic health conditions, including mental health conditions or substance use disorders. Miniaturization of complex hardware to enable broader access to pediatric and other patient populations, as well as portability, such as diagnostic, treatment, imaging, or other devices.Platform Systems: Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs Novel molecular platform approaches, including the modulation of host systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes. New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed. Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The FY24 PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY24 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: The postdoctoral investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. The PI must have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of March 31, 2025. The PCRP strongly encourages applications from PIs who demonstrate a commitment to pursuing a career focused on prostate cancer health disparity research. Mentor(s): Applications must include at least one mentor appropriate to the proposed research project who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary mentor with a more robust track record in prostate cancer research and mentorship. Applications that focus on prostate cancer health disparity should include at least one mentor with experience in prostate cancer health disparity research. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. Projects that specifically address the FY24 PCRP Overarching Challenge to advance health equity and reduce disparities in prostate cancer are strongly encouraged. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. Researcher Development Plan: The PI must outline an individualized, prostate cancer-focused researcher development plan, which should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Early Investigator Research Award should not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.24M to fund approximately 13 Early Investigator Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports clinical research projects that extend or enhance existing breast cancer studies, requiring collaboration with consumer advocates to improve outcomes for patients and the community.